Vaxcyte Inc (PCVX) USD0.0013

Sell:$36.21Buy:$36.22$1.13 (3.02%)

NASDAQ:0.05%
Market closed | Prices delayed by at least 15 minutes
Sell:$36.21
Buy:$36.22
Change:$1.13 (3.02%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$36.21
Buy:$36.22
Change:$1.13 (3.02%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.

Key people

Andrew L. Guggenhime
President, Chief Financial Officer
Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
James Wassil
Executive Vice President, Chief Operating Officer
Mikhail Eydelman
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Harp Dhaliwal
Company's Chief Technical Operations Officer
Carlos V. Paya
Independent Chairman of the Board
Olivier Brandicourt
Independent Director
Annie Drapeau
Independent Director
John P. Furey
Independent Director
Halley E. Gilbert
Independent Director
Click to see more

Key facts

  • EPIC
    PCVX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US92243G1085
  • Market cap
    $4.72bn
  • Employees
    414
  • Shares in issue
    129.00m
  • Exchange
    NASDAQ
  • Index
    TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.